Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 222

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 222
---
 Registration Statement of which this prospectus forms a part is declared effective by the SEC;

(vi)15% of the Consideration Shares will be automatically released on the day that is 180 days after the Registration Statement of which this prospectus forms a part is declared effective by the SEC; and

(vii)10% of the Consideration Shares will be automatically released on the day that is 210 days after the Registration Statement of which this prospectus forms a part is declared effective by the SEC;

provided that any Consideration Shares that have not been released from the lock-up restriction in accordance with the foregoing on or before May 29, 2026, the nine-month anniversary of August 29, 2025, will be automatically released on such date.

The lock-up restrictions do not apply in connection with:

(i)transfers from a Selling Shareholder to their affiliates, family members, or any company, trust or other entity owned by or maintained for the benefit of such Selling Shareholder or any of its family members;

(ii)transfers occurring by operation of law or in connection with transactions arising as a result of the death or incapacitation of a Selling Shareholder;

(iii)pledges of the Consideration Shares as security for bona fide indebtedness of a Selling Shareholder; or

(iv)transfers made pursuant to a bona fide take-over bid or similar transaction made to all holders of the Company common shares, including without limitation, a merger, arrangement or amalgamation, involving a change of control of the Company and provided that in the event the take-over or acquisition transaction is not completed, the Consideration Shares shall remain subject to the lock-up restrictions described herein.

<div align='center'>153

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F.R. SECTION 200.83</div>

The foregoing description of the contractual lock-up restrictions does not purport to be complete and is qualified in its entirety by reference to the full text of the Definitive Agreement, which is filed as an exhibit to the Registration Statement of which this prospectus forms a part and is incorporated herein by reference.

<div align='center'>154

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F.R. SECTION 200.83

PLAN OF DISTRIBUTION</div>

This Registration Statement relates to the sale from time to time of up to 1,397,184 common